Three-year agreement designed to help pharma company manage extensive pipeline
RESEARCH TRIANGLE PARK, N.C., May 12 /PRNewswire/ -- Quintiles
Transnational Corp. today announced it has entered a partnership with Roche
for clinical study management services.
The two companies have signed a three-year preferred provider agreement,
which will give Roche more flexibility and efficiency in the development of
its product pipeline. Analysts regard the Roche pipeline as among the best in
the pharmaceutical industry, with medications for diabetes, hepatitis, anemia,
rheumatoid arthritis and cancer among those in development.
"This agreement is very important because it may bring a number of new
molecular entities to patients sooner," said G. Stephen DeCherney, M.D., MPH,
President, Clinical Development Services Americas for Quintiles. "The
partnership will enable Quintiles and Roche to make more efficient use of
Quintiles' therapeutic expertise and global resources."
"By selecting Quintiles as a partner to manage clinical studies, we are
well positioned to successfully handle a substantial increase for new studies
in many therapeutic areas," said Dan Zabrowski, Vice President and Global Head
of Pharma Development Operations for Roche. "We believe this partnership will
greatly improve our flexibility and efficiency, which should bring more
medicines to patients more quickly."
Quintiles and Roche have established committees at various levels to
assure the success of the partnership and the development programs conducted
under the agreement. Each of the three committees has equal representation
from Roche and Quintiles.
About Quintiles
Quintiles helps improve healthcare worldwide by providing a broad range of
professional services, information and partnering solutions to the
pharmaceutical, biotechnology and healthcare industries. Headquartered near
Research Triangle Park, North Carolina, Quintiles has offices in 50 countries
and is the world's leading pharmaceutical services organization. For more
information visit the company's Web site at http://www.quintiles.com .
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As a supplier of innovative products and services for the early
detection, prevention, diagnosis and treatment of disease, the Group
contributes on a broad range of fronts to improving people's health and
quality of life. Roche is a world leader in diagnostics, the leading supplier
of medicines for cancer and transplantation and a market leader in virology.
In 2004 sales by the Pharmaceuticals Division totaled 21.7 billion Swiss
francs, while the Diagnostics Division posted sales of 7.8 billion Swiss
francs. Roche employs roughly 65,000 people in 150 countries and has R&D
agreements and strategic alliances with numerous partners, including majority
ownership interests in Genentech and Chugai.
SOURCE Quintiles Transnational Corp.
 back to top
Related links:
http://www.quintiles.com
CONTACT:
Media Relations, Dick Jones, +1-919-998-2091,
or media.info@quintiles.com , or Investor Relations, Greg
Connors, +1-919-998-2000, or invest@quintiles.com , both of
Quintiles Transnational Corp.
|
